

Sophie Degroote¹, Evy Blomme², Liesbeth Delesie¹, Linos Vandekerckhove^{1,2}, Marie-Angélique De Scheerder¹

¹University Hospital Ghent, Ghent, Belgium, ²HIV Cure Research Center, Ghent University, Ghent, Belgium

Contact: sophie.degroote@uzgent.be

BACKGROUND



DYAD

- ▶ Above switch-studies show non-inferior virological efficacy of DTG/3TC versus 3/4 drug regimens as well as its safety and tolerability
- ▶ 2nd generation integrase inhibitors and tenofovir alafenamide (TAF) have been associated with weight gain


Weight gain ?

Lipid changes ?

Impact of NRTI

MATERIALS & METHODS

- ▶ RUMBA study: Phase 4 RCT with analysis of **viral reservoir as primary endpoint**
- ▶ Virologic suppressed participants were 2:1 randomized to switch to DTG/3TC or switch to or stay on B/F/TAF
- ▶ **Metabolic outcomes as secondary endpoints**
- ▶ W48 results (virologic, metabolic, immunologic) recently published [1]
- ▶ Ordinary linear regression models with multiple imputations
- ▶ Differences in metabolic outcomes between **W144** and baseline are reported here



RESULTS

Population

Randomized: 134 → ITT-E: 130 → W48: 121 → W144: 103

	Total (n=130)	B/F/TAF (n=43)		DTG/3TC (n=87)	
Sex, M/F	118/12	39/4	79/8		
Ethnicity, European/African/Other	102/14/14	32/5/6	70/9/8		
Age, y, median (IQR)	47 (37-55)	46 (38-52)	48 (40-56)		
Time on ART, y, median (IQR)	7.2 (4.6-10.8)	6 (4.4-9.0)	8.6 (5.2-11.5)		
BMI, kg/m ² , median (IQR)	25 (23-28)	25 (22-26)	26 (23-28)		
<1y on 2 nd gen INSTI	15	4	11		
TAF naïve / <1y on TAF	49/11	21/4	28/7		



Baseline characteristics of the RUMBA participants

Outcomes


	Treatment ratio 3DR/2DR			B/F/TAF			DTG/3TC		
	Estimate	95% LCL	95% UCL	Estimate	95% LCL	95% UCL	Estimate	95% LCL	95% UCL
Weight	1	0.96	1.04	1.01	0.92	1.11	1.01	0.92	1.11
Cholesterol/HDL	1.04	0.93	1.16	1.14	0.9	1.43	1.09	0.86	1.37
Trunk lean mass	0.98	0.95	1.01	0.99	0.93	1.07	1.02	0.95	1.09
Fat%	1.05	0.99	1.11	1.04	0.91	1.2	1	0.87	1.14
HOMA-IR	0.93	0.68	1.25	0.8	0.4	1.6	0.87	0.46	1.64
FibroCap	1	0.93	1.08	0.94	0.81	1.08	0.94	0.82	1.08

Metabolic changes after 144 weeks, corrected for baseline response value, baseline regimen and baseline BMI. LCL: Lower confidence interval limit UCL: Upper confidence interval limit

Previous regimens



6 secondary metabolic outcomes were evaluated.
No statistically significant differences were observed between the two arms.



RUMBA VERSUS OTHER DTG/3TC TRIALS



W144: Favorable lipids in DTG/3TC vs TAF-containing 3-4DR

Prior regimens: 78% INSTI; 100% TAF

RUMBA: 68% switch off TAF in DTG/3TC group
No differences in lipids found



W48: More weight gain in DTG/3TC vs 3-4DR (adjusted weight difference 1.5kg)

Prior regimens: 40% INSTI (27% 2nd gen) 35% TAF; 44% TDF

RUMBA: no TDF-containing baseline regimens



W48: More weight gain in B/F/TAF vs DTG/3TC (adjusted difference 0.92kg)

Mainly in subgroups switching off ABC or TDF

Prior regimens: 17% INSTI (0% 2nd gen) 28% TAF; 35% TDF

RUMBA: W48 More increase in fat% in subgroup switching from DTG/ABC/3TC to B/F/TAF (+4% vs. +1%)
W144: no significant changes



W48: No differences in weight changes between DTG/3TC and B/F/TAF

Prior regimen: B/F/TAF (INSTI & TAF)

RUMBA: subgroup B/F/TAF as baseline regimen:
W48 & W144 no differences in weight changes between DTG/3TC and B/F/TAF arm

CONCLUSIONS & CONSIDERATIONS

- ▶ RUMBA's **week 48** data showed that switching to DTG/3TC had **no impact on the viral reservoir**. **Metabolic outcomes were comparable** between 2DR and 3DR, with slightly better body composition measures in 2DR [1].
- ▶ At **week 144**, we confirm **reassuring metabolic outcomes** in both the DTG/3TC and B/F/TAF group. **No statistically significant differences** are found.
- ▶ Metabolic outcomes in DTG/3TC switch trials depend mostly on baseline regimen.
- ▶ Metabolic outcomes should be further investigated to better understand their role and individualize treatment in people with increased risk of metabolic comorbidity.
- ▶ We await further RUMBA W144 analyses, with multiple imputations based on all intermediate data (week 72, 96 and 120) as well as W240 data.

The authors thank Viiv Healthcare for their support